A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode

Endocrinology

Volumn 152, Issue 6, 2011, Pages 2174-2183

  Reeb, Christina A ^a   Gerlach, Claudia ^a   Heinssmann, Maria ^a   Prade, Ina ^a   Ceraline, Jocelyn ^a,b   Roediger, Julia ^a   Roell, Daniela ^a   Baniahmad, Aria ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PEPTIDE APTAMER; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA VECTOR; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAMMAL CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSACTIVATION; YEAST;

APTAMERS, PEPTIDE; CELL LINE, TUMOR; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; DOWN-REGULATION; HUMANS; MALE; PERMEABILITY; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SPECIES SPECIFICITY; TRANSCRIPTIONAL ACTIVATION;

EID: 79956323048     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2011-0149     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics. CA Cancer J Clin 58:71-96
2. Brinkmann AO, Trapman J 2000 Prostate cancer schemes for androgen escape. Nat Med 6:628-629 (Pubitemid 30398780)
3. Ntais C, Polycarpou A, Tsatsoulis A 2003 Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 149:469-477 (Pubitemid 38054690)
4. Dehm SM, Tindall DJ 2007 Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21:2855-2863 (Pubitemid 350223500)
5. Burke LJ, Baniahmad A 2000 Co-repressors 2000. FASEB J 14:1876-1888
6. Burd CJ, Morey LM, Knudsen KE 2006 Androgen receptor core-pressors and prostate cancer. Endocr Relat Cancer 13:979-994 (Pubitemid 46212560)
7. Moehren U, Papaioannou M, Reeb CA, Hong W, Baniahmad A 2007 Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol 21:1039-1048 (Pubitemid 46984757)
8. Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A 2009 Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cells growth in the presence of antiandrogens. J Mol Endocrinol 42:429-435
9. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45 (Pubitemid 33741879)
10. Denmeade SR, Isaacs JT 2002 A history of prostate cancer treatment. Nat Rev Cancer 2:389-396 (Pubitemid 37328952)
11. Liao X, Tang S, Thrasher JB, Griebling TL, Li B 2005 Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505-515 (Pubitemid 40601831)
12. Baek SH, Ohgi KA, Nelson CA, Welsbie D, Chen C, Swayers CL, Rose DW, Rosenfeld MG 2006 Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci USA 103:3100-3105 (Pubitemid 43346431)
13. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
14. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153 (Pubitemid 36070433)
15. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E 1992 The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to anti-androgens. J Steroid Biochem Mol Biol 41:665-669
16. Craft N, Shostak Y, Carey M, Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285 (Pubitemid 29124362)
17. Sadar MD 1999 Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783
18. Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhi JA, Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16:661-673 (Pubitemid 34297738)
19. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H 2008 Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 27:3596-3604 (Pubitemid 351793796)
20. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319 (Pubitemid 32685750)
21. Baines IC, Colas P 2006 Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today 11:334-341
22. Hoppe-Seyler F, Butz K 2000 Peptide aptamers: powerful new tools for molecular medicine. J Mol Med 78:426-430
23. Harada H, Kizaka-Kondoh S, Hiraoka M 2006 Antitumor protein therapy: application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 13:16-26
24. Patel LN, Zaro JL, Shen WC 2007 Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharmaceutical Research 24:1977-1992 (Pubitemid 47493563)
25. Kang Z, Jänne OA, Palvimo JJ 2004 Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 18:2633-2648 (Pubitemid 39482054)
26. Kamitani T, Nguyen HP, Yeh ET 1997 Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. J Biol Chem 272:14001-14004
27. Yang SH, Sharrocks AD 2004 SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 13:611-617 (Pubitemid 38299387)
28. Roisin A, Robin JP, Dereuddre-Bosquet N, Vitte AL, Dormont D, Clayette P, Jalinot P 2004 Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. J Biol Chem 279:9208-9214 (Pubitemid 38295984)
29. Bohne J, Cathomen T 2008 Genotoxicity in gene therapy: an account of vector integration and designer nucleases. Curr Opin Mol Ther 10:214-223 (Pubitemid 351799272)
30. Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A 2003 Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 213:79-85 (Pubitemid 38229157)
31. Goeman F, Baniahmad A 2004 Mechanisms of nuclear hormone receptor signaling. Mechanisms of Signal Transduction and Inducible Gene Expression, Research Signpost ISBN 81-7736-162-7:53-76
32. Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, Salis A, Chiossone L, Mingari MC, Orecchia P, Carnemolla B, Neri D, Zardi L, Parodi S 2008 Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 22:1237-1245 (Pubitemid 351519977)
33. Kunz C, Borghouts C, Buerger C, Groner B 2006 Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Mol Cancer Res 4:983-998
34. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM 2008 A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Research 68:645-649 (Pubitemid 351206738)